Author:
Qiu H-B,Zhuang W,Wu T,Xin S,Lin C-Z,Ruan H-L,Zhu X,Huang M,Li J-L,Hou X-Y,Zhou Z-W,Wang X-D
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference51 articles.
1. Buchdunger E, O'Reilly T, Wood J . Pharmacology of imatinib (STI571). Eur J Cancer 2002; 385: S28–S36.
2. Wolter P, Schoffski P . Targeted therapies in the treatment of GIST: adverse events and maximising the benefits of sunitinib through proactive therapy management. ACTA ONCOL 2010; 49: 13–23.
3. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236–4243.
4. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90: 4947–4952.
5. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139–145.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献